Four million people were receiving anti-retroviral therapy (ART) in low- and middle-income countries by the end of 2008. At current survival rates, most of these patients can expect to live another twenty years or mabout 15 more years ore if they continue to receive treatment. The scale-up of treatment to daytoday implies a long-term commitment to continue support well into the future. This website provides tools and analysis to improve understanding of the extent of that commitment.
This Website is organized around five key questions related to the future commitment:
One Two Three Four Five


Click here to read the full paper, "The Costs of Anti-Retroviral Therapy in Low- and Middle-Income Countries: Present Commitments and Future Needs."